Document Type : Original Article

Authors

1 Undergraduate Student, School of Dentistry, International Branch, Shiraz University of Medical Sciences, Shiraz, Iran.

2 Oral and Dental Disease Research Center, Dept. of Oral and Maxillofacial Pathology, School of Dentistry, Shiraz University of Medical Sciences, Shiraz, Iran.

3 Postgraduate, Dept. of Oral and Maxillofacial Pathology, School of Dentistry, Shiraz University of Medical Sciences, Shiraz, Iran.

4 Dept. of Oral and Maxillofacial Pathology, School of Dentistry, Shiraz University of Medical Sciences, Shiraz, Iran.

5 Dept. of Otorhinolaryngology, Khalili Hospital, Shiraz Institute for Cancer Research, Shiraz University of Medical Sciences, Shiraz, Iran.

6 Shiraz Institute for Cancer Research, Shiraz University of Medical Sciences, Shiraz, Iran.

Abstract

Statement of the Problem: Heat shock protein 27 (HSP27) plays important roles in many cellular processes and has been implicated in different types of diseases such as cancers.
Purpose: This study aimed to evaluate the serum level of HSP27 in patients with salivary gland tumors and to determine its possible correlation with the prognosis of the disease.
Materials and Method: This cross-sectional study was performed on 60 patients with salivary gland tumor including 16 pleomorphic adenoma, 33 adenoid cystic carcinoma, 6 mucoepidermoid carcinoma, 5 acinic cell carcinoma, and 28 healthy control subjects. The control cases were healthy blood donors who matched the study group in age and sex. Serum samples were obtained from the clotted blood and HSP27concentrations were measured with sandwich enzyme-linked immunosorbent assay (ELISA). Statistical analysis was performed by using one-way ANOVA, post Hoc test, independent sample t-test, and ROC analysis. A p value of less than 0.05 was considered as significant.
Results: The mean serum level of HSP27 was 3956.1±3830.1 (pg/ml) in patients with malignant salivary gland tumor, which was significantly higher than that in benign salivary gland tumor (752.2±485.6) and healthy controls (602.3±575.8) (p< 0.001). However, there was no significant difference in the HSP27 serum levels between the patients with benign salivary gland tumors and healthy controls (p= 0.2). No association was detected between the mean serum levels of HSP27 and clinicopathologic factors such as age, sex, stage and nodal metastasis (p> 0.05), except for the tumor size (p= 0.04).
Conclusion: The HSP27 concentration increased in patients with malignant salivary gland tumors. Moreover, the HSP27 level was correlated with tumor growth, invasiveness, and diagnosability. Yet, larger clinical studies are required to explore its prognostic value.

Keywords

  •  

    • Gruden G, Carucci P, Lolli V, Cosso L, Dellavalle E, Rolle E, et al. Serum heat shock protein 27 levels in patients with hepatocellular carcinoma. Cell Stress Chaperones. 2013; 18: 235-241.
    • Feng JT, Liu YK, Song HY, Dai Z, Qin LX, Almofti MR, et al. Heat-shock protein 27: a potential biomarker for hepatocellular carcinoma identified by serum proteome analysis. Proteomics. 2005; 5: 4581-4588.
    • Banerjee S, Lin CF, Skinner KA, Schiffhauer LM, Peacock J, Hicks DG, et al. Heat shock protein 27 differentiates tolerogenic macrophages that may support human breast cancer progression. Cancer Res. 2011; 71: 318-327.
    • Kepenekian V, Aloy MT, Magne N, Passot G, Armandy E, Decullier E, et al. Impact of hyperthermic intraperitoneal chemotherapy on Hsp27 protein expression in serum of patients with peritoneal carcinomatosis. Cell Stress Chaperones. 2013; 18: 623-630.
    • Wang G, Gu X, Chen L, Wang Y, Cao B, E Q. Comparison of the expression of 5 heat shock proteins in benign and malignant salivary gland tumor tissues. Oncol Lett. 2013; 5: 1363-1369.
    • Baumhoer D, Tornillo L, Stadlmann S, Roncalli M, Diamantis EK, Terracciano LM. Glypican 3 expression in human nonneoplastic, preneoplastic, and neoplastic tissues: a tissue microarray analysis of 4,387 tissue samples. Am J Clin Pathol. 2008; 129: 899-906.
    • Khalil AA, Kabapy NF, Deraz SF, Smith C. Heat shock proteins in oncology: diagnostic biomarkers or therapeutic targets? Biochim Biophys Acta. 2011; 1816: 89-104.
    • Scroggins BT, Robzyk K, Wang D, Marcu MG, Tsutsumi S, Beebe K, et al. An acetylation site in the middle domain of Hsp90 regulates chaperone function. Molecular cell. 2007; 25: 151-159.
    • Jiang Y, Wang X, Guo Y, Li W, Yang S, Li W, et al. Expression of Heat Shock Protein 27 in Benign Prostatic Hyperplasia with Chronic Inflammation. Med Sci Monit. 2015; 21: 2976-2985.
    • Korneeva I, Bongiovanni AM, Girotra M, Caputo TA, Witkin SS. Serum antibodies to the 27-kd heat shock protein in women with gynecologic cancers. Am J Obstet Gynecol MFM. 2000; 183: 18-21.
    • Wang F, Jing X, Wang T, Li G, Li T, Zhang Q, et al. Differential diagnostic value of GPC3-CD34 combined staining in small liver nodules with diameter less than 3 cm. Am J Clin Pathol 2012; 137: 937-945.
    • Saikali Z, Sinnett D. Expression of glypican 3 (GPC3) in embryonal tumors. Int J Cancer. 2000; 89: 418-422.
    • Vidyasagar A, Reese S, Acun Z, Hullett D, Djamali A. HSP27 is involved in the pathogenesis of kidney tubulointerstitial fibrosis. Am J Physiol Renal Physiol. 2008; 295: F707-F716.
    • Ghayour-Mobarhan M, Saber H, Ferns GA. The potential role of heat shock protein 27 in cardiovascular disease. Clinica chimica acta. Clin Chim Acta. 2012; 413: 15-24.
    • Guo QY, Yuan M, Peng J, Cui XM, Song G, Sui X, et al. Antitumor activity of mixed heat shock protein/ peptide vaccine and cyclophosphamide plus interleukin-12 in mice sarcoma. J Exp Clin Cancer Res CR. 2011; 30: 24.
    • Park SJ, Kostic M, Dyson HJ. Dynamic Interaction of Hsp90 with Its Client Protein p53. J Mol Biol. 2011; 411: 158-173.
    • Grozdanov PN, Yovchev MI, Dabeva MD. The oncofetal protein glypican-3 is a novel marker of hepatic progenitor/oval cells. Lab Invest. 2006; 86: 1272-1284.
    • Madu CO, Lu Y. Novel diagnostic biomarkers for prostate cancer. J Cancer. 2010; 1: 150-177.
    • Gehrmann M, Cervello M, Montalto G, Cappello F, Gulino A, Knape C, et al. Heat shock protein 70 serum levels differ significantly in patients with chronic hepatitis, liver cirrhosis, and hepatocellular carcinoma. Front Immunol. 2014; 5: 307.
    • Beere HM. "The stress of dying": the role of heat shock proteins in the regulation of apoptosis. J Cell Sci. 2004; 117: 2641-2651.
    • Van*Eden W, van*der*Zee R, Prakken B. Heat-shock proteins induce T-cell regulation of chronic inflammation. Nat Rev Immunol. 2005; 5: 318-330.
    • Ciocca DR, Calderwood SK. Heat shock proteins in cancer: diagnostic, prognostic, predictive, and treatment implications. Cell Stress Chaperones. 2005; 10: 86-103.
    • Calderwood SK, Khaleque MA, Sawyer DB, Ciocca DR. Heat shock proteins in cancer: chaperones of tumorigenesis. Trends Biochem Sci. 2006; 31: 164-172.
    • Arrigo AP, Simon S, Gibert B, Kretz-Remy C, Nivon M, Czekalla A, et al. Hsp27 (HspB1) and alphaB-crystallin (HspB5) as therapeutic targets. FEBS Lett. 2007; 581: 3665-3674.
    • Shirakawa H, Suzuki H, Shimomura M, Kojima M, Gotohda N, Takahashi S, et al. Glypican‐3 expression is correlated with poor prognosis in hepatocellular carcinoma. Cancer science. 2009; 100: 1403-1407.
    • Foda AARM, Mohammad MA, Abdel-Aziz A, El-Haw-ary AK. Relation of glypican-3 and E-cadherin expressions to clinicopathological features and prognosis of mucinous and non-mucinous colorectal adenocarcinoma. Tumor Biology. 2015; 36: 4671-4679.
    • Romani AA, Crafa P, Desenzani S, Graiani G, Lagrasta C, Sianesi M, et al. The expression of HSP27 is associated with poor clinical outcome in intrahepatic cholangio-carcinoma. BMC Cancer. 2007; 7: 232.
    • Howe HL, Wingo PA, Thun MJ, Ries LA, Rosenberg HM, Feigal EG, et al. Annual report to the nation on the status of cancer (1973 through 1998), featuring cancers with recent increasing trends. J Natl Cancer Inst. 2001; 93: 824-842.
    • Melle C, Ernst G, Escher N, Hartmann D, Schimmel B, Bleul A, et al. Protein profiling of microdissected pancreas carcinoma and identification of HSP27 as a potential serum marker. Clin Chem. 2007; 53: 629-635.
    • De*Cat B, Muyldermans SY, Coomans C, Degeest G, Vanderschueren B, Creemers J, et al. Processing by proprotein convertases is required for glypican-3 modulation of cell survival, Wnt signaling, and gastrulation movements. J Cell Biol. 2003; 163: 625-635.
    • Zimmermann M, Nickl S, Lambers C, Hacker S, Mitterba-uer A, Hoetzenecker K, et al. Discrimination of clinical sta-ges in non-small cell lung cancer patients by serum HSP27 and HSP70: a multi-institutional case-control study. Clinica chimica acta; Clin Chim Acta. 2012; 413: 1115-1120.
    • De AK, Roach SE. Detection of the soluble heat shock protein 27 (hsp27) in human serum by an ELISA. J Immunoassay Immunochem. 2004; 25: 159-170.
    • Liao WC, Wu MS, Wang HP, Tien YW, Lin JT. Serum heat shock protein 27 is increased in chronic pancreatitis and pancreatic carcinoma. Pancreas. 2009; 38: 422-426.
    • Srivastava P. Interaction of heat shock proteins with peptides and antigen presenting cells: chaperoning of the innate and adaptive immune responses. Annu Rev Immunol. 2002; 20: 395-425.
    • Seethala RR. An update on grading of salivary gland carcinomas. Head Neck Pathol. 2009; 3: 69-77.
    • Peters M, Farias E, Colombo L, Filmus J, Puricelli L, de Kier Joffe EB. Inhibition of invasion and metastasis by glypican-3 in a syngeneic breast cancer model. Breast Cancer Res Treat. 2003; 80: 221-32.
    • Arnal ME, Lalles JP. Gut epithelial inducible heatshock proteins and their modulation by diet and the microbiota. Nutr Rev. 2016; 74: 181-197.
    • Zhao M, Ding JX, Zeng K, Zhao J, Shen F, Yin YX, et al. Heat shock protein 27: a potential biomarker of peritoneal metastasis in epithelial ovarian cancer? Tumour biology: Tumour Biol. 2014; 35: 1051-1056.
    • Ota T, Ota K, Jono H, Fujimori H, Ueda M, Shinriki S, et al. Midkine expression in malignant salivary gland tumors and its role in tumor angiogenesis. Oral Oncol. 2010; 46: 657-661.